Indoco Remedies Q1FY27 profit jumps on ₹97cr asset sale

Key takeaway from the June quarter

Indoco Remedies Ltd reported a sharp year-on-year swing to profit for the quarter ended June 30, 2026 (Q1FY27), but the improvement was largely driven by a one-time gain from an asset sale. The company posted a standalone net profit of ₹8.23 crore, compared with a net loss of ₹2.81 crore in Q1FY26. The result highlights a clear split between reported profitability and underlying operating performance, as the company said the exceptional item was central to the quarter’s bottom line.

The Board of Directors approved the unaudited standalone and consolidated financial results at its meeting on July 28, 2026. The results were reviewed by the Audit Committee and were subject to a limited review by statutory auditors Gokhale & Sathe, Chartered Accountants, who issued an unmodified opinion.

Standalone results: revenue up, margins improve

On a standalone basis, revenue from operations rose 5.8% year-on-year to ₹40.81 crore, compared with ₹38.56 crore in Q1FY26. The company reported an improvement in EBITDA margin to 10.3% from 3.8% in the corresponding quarter last year.

Alongside the margin change, the article also states EBITDA of ₹422 million in Q1FY27 versus ₹148 million in Q1FY26. Readers should note that these EBITDA amounts are presented in a different unit than the revenue figures disclosed in ₹ lakh in the same update.

Profit recovery driven by exceptional gain

The quarter’s headline profit was mainly supported by an exceptional gain of ₹97.34 crore recognised from the slump sale of Indoco’s Ophthalmic Business Division to Sunways (India) Private Limited. The company’s standalone net profit of ₹8.23 crore reflected the benefit of this one-time item.

The same filing also indicates operational stress beneath the headline number. Excluding the exceptional gain, Indoco recorded a loss before tax of ₹4.12 crore. This gap matters because it suggests the profit turnaround did not come from a broad-based improvement in core operations during the quarter.

Domestic and export split in Q1FY27

Within standalone revenue, domestic sales contributed ₹22.78 crore while exports accounted for ₹18.04 crore. The split shows that the company continued to lean on both home and overseas markets for volumes, even as the quarter’s profitability was largely influenced by non-operating income.

The rise in EBITDA margin, as disclosed, points to improved cost management and mix shifts during the quarter. But the pre-exceptional loss number indicates that these improvements were not enough to deliver a positive pre-tax result without the divestment gain.

Consolidated performance: profit attributable turns positive

On a consolidated basis, revenue from operations increased 8.2% year-on-year to ₹46.62 crore, compared with ₹43.09 crore in Q1FY26. Domestic sales were ₹31.18 crore, while international sales were ₹15.45 crore.

Consolidated net profit attributable to equity shareholders stood at ₹6.50 crore, reversing a loss of ₹3.58 crore in Q1FY26. The consolidated results also benefited from the same exceptional gain of ₹97.34 crore linked to the ophthalmic business sale.

Auditor note: going-concern risk flagged for subsidiary

While the auditors issued an unmodified opinion on the limited review, they flagged a material uncertainty related to the going-concern status of subsidiary FPP Holding LLC. The update states FPP Holding LLC continued to have a negative net worth of ₹38.23 crore, despite posting a net profit of ₹3.01 crore for the quarter.

This disclosure is relevant for investors tracking consolidated financial health, because a negative net worth and a going-concern emphasis can influence how the market assesses risk, even when the parent reports a profit driven by exceptional items.

Stock snapshot and market context

The stock was shown at ₹234.85 on the BSE at 04:01 PM, down ₹9.70 or 3.97% for the day. The day’s low was ₹234.25. The 52-week high and low were listed as ₹348.1 and ₹163.7, respectively.

The same page also mentioned a current share price of ₹235.64 and a market capitalisation of ₹2,175.04214822 crore. It listed face value at ₹2 and book value per share at about ₹119.0843.

Key numbers from Q1FY27 (as disclosed)

*Consolidated figures represent profit attributable to equity shareholders.

Why this quarter stands out

The Q1FY27 update underscores how a single corporate action can reshape quarterly earnings. Indoco’s reported profit was supported by an asset divestment, while the business (excluding exceptional items) reported a loss before tax. For analysts, that distinction is important when separating recurring operating performance from one-off gains.

At the same time, the auditors’ emphasis on going-concern uncertainty at a subsidiary adds a second layer of scrutiny. Even with an unmodified limited review, such flags can keep attention on balance sheet strength and sustainability of earnings in future quarters.

What to watch next

Investors will likely track how Indoco’s operating performance evolves in subsequent quarters, particularly whether the company can convert improved margins into positive profit without exceptional income. The next set of quarterly results and any further disclosures around subsidiaries and financial position will be key datapoints, given the going-concern note for FPP Holding LLC.

Conclusion

Indoco Remedies’ Q1FY27 profit swing was driven primarily by the ₹97.34 crore gain from selling its Ophthalmic Business Division, while core performance remained weak on a pre-exceptional basis. The July 28, 2026 board approval and the auditor note on a subsidiary’s negative net worth keep focus on underlying fundamentals and group-level risks.